Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Immutep (ASX:IMM) has reported that eftilagimod alpha (efti) combined with MSD's KEYTRUDA® shows high efficacy and a favourable safety profile for treating head and neck cancer. The TACTI-003 trial ...

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...

Summit Therapeutics’s drug ivonescimab reduced the risk of lung cancer progression or death by nearly half, compared to MSD’s blockbuster drug Keytruda (pembrolizumab ... China-based pharma company ...

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

You know the Detroit Lions have arrived when their head coach is starring in a commercial for a major restaurant chain. Dan Campbell was front and center in a new ad for Applebee's that was ...

Merck's Keytruda therapy received approval from the European Union, in combination with antibody-drug Padcev, as a first-line cancer treatment. The pharmaceutical company said Tuesday that the ...